Literature DB >> 27364045

Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis.

Arnt V Kristen1, Eva Brokbals2, Fabian Aus dem Siepen2, Ralf Bauer2, Selina Hein2, Matthias Aurich2, Johannes Riffel2, Hans-Michael Behrens3, Sandra Krüger3, Peter Schirmacher4, Hugo A Katus5, Christoph Röcken3.   

Abstract

BACKGROUND: Cardiac amyloid load has not been analyzed for its effect on mortality in patients with amyloid light-chain (AL) cardiac amyloidosis.
OBJECTIVES: This study retrospectively compared histological amyloid load with common clinical predictors of mortality.
METHODS: This study assessed 216 patients with histologically confirmed cardiac amyloidosis at a single center with electrocardiography, echocardiography, and laboratory testing.
RESULTS: AL amyloid deposits were usually distributed in a reticular/pericellular pattern, whereas transthyretin amyloid (ATTR) more commonly showed patchy deposits. Median amyloid load was 30.5%; no amyloid load was above 70%. During follow-up (median 19.1 months), 112 patients died. Chemotherapy had a significant effect on overall survival in AL amyloidosis (16.2 months vs. 1.4 months; p = 0.003). Patients with <20% AL amyloid load who responded to chemotherapy showed significantly better survival than nonresponders. According to univariate analysis, predictors of survival in AL amyloidosis included sex, Karnofsky index, New York Heart Association (NYHA) functional class, diastolic blood pressure, estimated glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor antagonists, low voltage, ineligibility for chemotherapy, response to chemotherapy, and amyloid load. Independent predictors of mortality by multivariate analysis included NYHA functional class (III vs. II), estimated glomerular filtration rate, responders to chemotherapy, and amyloid load. In ATTR amyloidosis, survival correlated with NYHA functional class, diastolic blood pressure, and use of diuretic agents. Following Cox regression analysis, NYHA functional class (III vs. II; p < 0.05) remained the only independent predictor of patient survival in ATTR amyloidosis.
CONCLUSIONS: Early identification of subjects with AL amyloid is essential given that in late-stage disease with extensive amyloid load, our data suggested that outcomes are not affected by administration of chemotherapy.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amyloidosis; endomyocardial biopsy; immunohistochemistry; light-chain amyloid; survival; transthyretin

Mesh:

Substances:

Year:  2016        PMID: 27364045     DOI: 10.1016/j.jacc.2016.04.035

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

1.  Setting the stage for the next step in cardiac amyloidosis imaging: Serial quantitative studies to assess disease activity.

Authors:  Prem Soman; Ahmad Masri
Journal:  J Nucl Cardiol       Date:  2017-03-17       Impact factor: 5.952

2.  A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters.

Authors:  Priya Mehta; David B Chapel; Neha Goyal; Dong Bo Yu; Victor Mor-Avi; Akhil Narang; Karima Addetia; Nitasha Sarswat; Roberto M Lang; Aliya N Husain; Amit R Patel
Journal:  Echocardiography       Date:  2018-12-28       Impact factor: 1.724

3.  Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management.

Authors:  Julius-Valentin Baumgart; Christiane Stuhlmann-Laeisz; Ute Hegenbart; Johanna Nattenmüller; Stefan Schönland; Sandra Krüger; Hans-Michael Behrens; Christoph Röcken
Journal:  Virchows Arch       Date:  2018-08-22       Impact factor: 4.064

4.  Macrophage-Mediated Phagocytosis and Dissolution of Amyloid-Like Fibrils in Mice, Monitored by Optical Imaging.

Authors:  Tina Richey; James S Foster; Angela D Williams; Anna B Williams; Alexa Stroh; Sallie Macy; Craig Wooliver; R Eric Heidel; Siva K Varanasi; Elizabeth N Ergen; Dianne J Trent; Stephen A Kania; Stephen J Kennel; Emily B Martin; Jonathan S Wall
Journal:  Am J Pathol       Date:  2019-02-06       Impact factor: 4.307

Review 5.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  Cardiac Amyloidosis: Diagnosis and Treatment Strategies.

Authors:  Mirela Tuzovic; Eric H Yang; Arnold S Baas; Eugene C Depasquale; Mario C Deng; Daniel Cruz; Gabriel Vorobiof
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

Review 7.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 8.  Current and future circulating biomarkers for cardiac amyloidosis.

Authors:  Marco Luciani; Luca Troncone; Federica Del Monte
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

9.  Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study.

Authors:  Virgile Chevance; Thibaud Damy; Vania Tacher; François Legou; Fourat Ridouani; Alain Luciani; Hicham Kobeiter; Alain Rahmouni; Jean-François Deux
Journal:  Eur Radiol       Date:  2017-08-10       Impact factor: 5.315

10.  In Search of the Holy Grail: Evidence of Amyloid Fibril Regression in ATTR Cardiac Amyloidosis.

Authors:  Frederick L Ruberg; Omar K Siddiqi
Journal:  JACC Cardiovasc Imaging       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.